A comparison of a 5% @entity4014 solution with a @entity1487 and XXXX combination in the treatment of @entity1 with @entity4891 : a randomized, open-label clinical trial.

@entity1 @entity3071 @entity3785 @entity4891 @entity4014 @entity1082 @entity1487
Anogenital warts are caused by @entity1082 ), over 30 types of which are infectious for the anogenital tract. Without treatment, warts may regress spontaneously, remain unchanged, or increase in number and size. This study compared the efficacy of a topical 5% @entity4014 ( @entity3071 ) solution with that of a topical 0.5% @entity1487 ( @entity1487 ) and 10% @entity3785 (SA) combination in the treatment of @entity4891 . Sixty @entity1 were randomly assigned to receive topical @entity3071 or @entity1487  +  SA. Both groups demonstrated a significant decrease in numbers of lesions (P  <  0.05), but this difference was not significant at week 12 (P  >  0.05). The mean number of lesions decreased from baseline to week 12 from 17.03      12.64 to 3.73      7.30 and from 16.13      12.97 to 3.10      4.90 in the @entity3071 and @entity1487  +  SA groups, respectively (P  <  0.001). Excellent clearance was achieved by 70.0 and 76.7% of @entity1 in the @entity3071 and @entity1487  +  SA groups, respectively. Marked improvement was seen in 13.3 and 20.0% of @entity1 in the @entity3071 and @entity1487  +  SA groups, respectively. At week 16, relapse was observed in two @entity1 in the @entity3071 group and three in the @entity1487  +  SA group (P  >  0.05). No serious adverse events were reported. Neither treatment was more efficacious. Safety and ease of application are important goals in treatments for @entity4891 . A 5% @entity3071 solution is a promising alternative treatment because it is effective and inexpensive and causes minimal side effects.
